53 results
8-K
EX-10.1
TPST
Tempest Therapeutics Inc
21 Jun 22
Departure of Directors or Certain Officers
7:31am
; (xxvii) debt levels; (xxviii) operating profit or net operating profit; (xxix) workforce diversity; (xxx) growth of net income or operating income
PRE 14A
2ofac6kr
22 Apr 22
Preliminary proxy
4:01pm
424B3
e0b fczcddlut
11 May 21
Prospectus supplement
5:19pm
8-K
EX-2.1
36m2oci oi
29 Mar 21
Tempest and Millendo Announce Proposed Merger Agreement
7:29am
425
EX-2.1
x7t 9ruaybct4xhr
29 Mar 21
Business combination disclosure
7:27am
8-K
u7seki 70b5qbuvc74
28 Jan 21
Cost Associated with Exit or Disposal Activities
8:01am
8-K
EX-10.1
k4safwq kscsl3c
28 Jan 21
Cost Associated with Exit or Disposal Activities
8:01am
8-K
EX-99.1
40pf6 bvwnnw
5 Jan 21
Millendo Therapeutics Provides Pipeline and Business Update
9:08am